Compounded GLP-1s Are Gone: What Changed and What Replaced Them

Why was compounding ever allowed?

Federal law generally prohibits a compounding pharmacy from preparing what amounts to a copy of a commercially available approved drug. There is a specific exception: when the drug appears on the FDA shortage list, compounders may step in to meet demand the manufacturer cannot.

That exception is what created the entire compounded GLP-1 market. Telehealth programmes selling semaglutide and tirzepatide at a fraction of brand pricing were operating inside a shortage carve-out, not inside a permanent right.

So resolving the shortage did not tighten a rule. It removed the foundation the market was standing on.

How did it actually unfold?

The FDA removed tirzepatide from the shortage list on 2 October 2024. A legal challenge from compounding interests led to a remand, and the agency reaffirmed its determination by declaratory order on 19 December 2024, with staged grace periods to allow an orderly wind-down.

Those grace periods expired on 18 February 2025 for state-licensed 503A pharmacies and 19 March 2025 for registered 503B outsourcing facilities. In May 2025 a federal court upheld the agency's shortage-resolution decision, closing the main avenue of challenge.

What about 'personalised' compounded versions?

Some sellers responded by adding an ingredient — vitamin B12 is the common example — or varying the dose slightly, on the argument that the result is no longer a copy. The FDA has treated preparations within a narrow range of the approved dose as essentially copies regardless of such additions.

For a buyer the practical point is narrower and more useful than the legal argument: a 'personalised' label does not establish that a product is lawfully supplied, and it certainly does not establish that it was ever tested. No randomised trial has evaluated any compounded GLP-1 preparation, personalised or otherwise. Every efficacy figure in circulation belongs to the approved product.

What should you do now?

If you are currently receiving a compounded product, speak to the prescriber who issued it before changing anything. Continuity of dose, supply and coverage are clinical questions, and stopping abruptly has its own consequences given the regain evidence.

Financially, expect an increase. The realistic routes are an insurance appeal, a manufacturer savings programme if you have commercial coverage, or the manufacturer's direct cash channel. The gap between a covered copay and a cash price is large enough that an appeal is usually the highest-value hour available.

How do you verify a seller that is still operating?

The single most useful question is which pharmacy dispenses, by legal name, with its state licence number. That is checkable against the licensing state board's public register in a couple of minutes, and it is the one claim a seller cannot fabricate without leaving a trace. A refusal to answer before payment is itself the answer.

After that, ask whether the facility is a 503A pharmacy or a 503B outsourcing facility, and for 503B claims check the FDA's outsourcing facility register. Ask for the concentration in milligrams per millilitre and the beyond-use date policy, since a compounded preparation carries pharmacy-assigned dating rather than a manufacturer expiry derived from formal stability testing.

None of these checks guarantees quality. What they do is replace a marketing claim with a public record. In a market where the usual guarantee — premarket regulatory review — does not apply, a verifiable supply chain is the strongest signal available to a consumer.

Frequently asked questions

Sources

• FDA declaratory order on tirzepatide shortage
• FDA — compounding and drug shortages

Every clinical claim above links to a primary source: an FDA record, a peer-reviewed publication with DOI or PMID, or a ClinicalTrials.gov registration. Where a figure could not be verified against a primary source, it is labelled rather than asserted.